- Home
- SGA vs IFRX Comparison
SGA vs IFRX Comparison
Compare SGA & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGA | IFRX |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 60.6M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SGA | IFRX |
|---|---|---|
| Price | $11.97 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 7.8K | ★ 282.8K |
| Earning Date | 03-12-2026 | 03-19-2026 |
| Dividend Yield | ★ 8.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,829,000.00 | N/A |
| Revenue This Year | $6.74 | $2,622.92 |
| Revenue Next Year | N/A | $120.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.65 | N/A |
| 52 Week Low | $10.68 | $0.71 |
| 52 Week High | $14.27 | $1.94 |
Technical Indicators
Market Signals| Indicator | SGA | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 48.00 |
| Support Level | $11.75 | $0.77 |
| Resistance Level | $11.99 | $1.16 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 85.22 | 41.96 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.